微生物生态系统疗法4 (MET4) 引起与肠道微生物群的变化相关的治疗特异性IgG反应,在免疫检查点抑制剂接受者中具有先进的固体瘤
Matthew K Wong1, Giselle M Boukhaled2, Eric Armstrong3
1Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Journal for immunotherapy of cancer
|March 22, 2025
概括
肠道细菌联盟MET4 (微生物生态系统治疗4) 在接受免疫治疗的癌症患者中诱导了特定抗体反应. 这表明肠道微生物可以增强抗瘤免疫力的机制.
科学领域:
- 免疫学 免疫学 免疫学
- 微生物组研究 微生物组研究
- 在瘤学瘤学.
背景情况:
- 肠道微生物组调制是增强癌症免疫疗法的有希望的策略.
- 肠道细菌影响全身和抗瘤免疫力的确切机制尚未完全理解.
研究的目的:
- 调查细菌联盟MET4如何影响接受免疫检查点抑制剂的患者的全身免疫.
- 评估在MET4治疗后诱导循环抗体反应和免疫细胞子集转移.
主要方法:
- 来自MET4-IO试验的血液和便样本的分析.
- 抗微生物抗体流动细胞测量试验以测量抗体反应.
- 用于便的分类学分析的元基因组测序和用于免疫细胞分析的质量细胞测量.
主要成果:
- MET4治疗导致循环抗MET4免疫球蛋白G (IgG) 反应增加.
- 较高的IgG反应与特定肠道类型的丰富性增加相关,包括*Collinsella aerofaciens*.
- 在高IgG反应者中观察到B细胞和FoxP3+ CD4+ T细胞增加,单细胞减少.
结论:
- 这项研究表明,细菌联盟可以诱导特定的循环幽默免疫.
- 这些发现表明了肠道微生物对抗瘤免疫力的潜在机制.
更多相关视频
00:07A Double Humanized BLT-mice Model Featuring a Stable Human-Like Gut Microbiome and Human Immune System
Published on: August 30, 2019
8.6K
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
548
相关概念视频
01:27Tumor Immunotherapy
454
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
454
01:29Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106